Cargando…

Catecholamines and Neurodegeneration in Parkinson’s Disease—From Diagnostic Marker to Aggregations of α-Synuclein

Parkinson’s disease is the second most prevalent disease of the brain. It is characterized by midbrain dopaminergic neuronal degeneration accompanied by Lewy bodies, intra-cytoplasmic neuronal inclusions that consist mainly of alpha-synuclein. The cardinal motor features are muscular rigidity, brady...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sawada, Hideyuki, Oeda, Tomoko, Yamamoto, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665535/ https://www.ncbi.nlm.nih.gov/pubmed/26835675 http://dx.doi.org/10.3390/diagnostics3020210

Ejemplares similares

Diagnostic Accuracy of Apparent Diffusion Coefficient and (123)I-Metaiodobenzylguanidine for Differentiation of Multiple System Atrophy and Parkinson’s Disease
por: Umemura, Atsushi, et al.
Publicado: (2013)

Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP)
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Models of α-synuclein aggregation in Parkinson’s disease
por: Giráldez-Pérez, Rosa María, et al.
Publicado: (2014)

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
por: Sawada, Hideyuki, et al.
Publicado: (2010)

Small molecules to prevent the neurodegeneration caused by α-synuclein aggregation
por: Peña-Díaz, Samuel, et al.
Publicado: (2020)

Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease
por: Sawada, Hideyuki, et al.
Publicado: (2015)

Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease
por: Umemura, Atsushi, et al.
Publicado: (2015)

Video-fluoroscopic swallowing study scale for predicting aspiration pneumonia in Parkinson’s disease
por: Tomita, Satoshi, et al.
Publicado: (2018)

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
por: Tatenhorst, Lars, et al.
Publicado: (2016)

Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson’s Disease
por: Mori, Akio, et al.
Publicado: (2020)

Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration
por: Davis, Marie Y., et al.
Publicado: (2016)

Clinical Factors Associated with Abnormal Postures in Parkinson's Disease
por: Oeda, Tomoko, et al.
Publicado: (2013)

Subclinical Elevation of Plasma C-Reactive Protein and Illusions/Hallucinations in Subjects with Parkinson’s Disease: Case–control Study
por: Sawada, Hideyuki, et al.
Publicado: (2014)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
por: Yuan, Xin, et al.
Publicado: (2022)

Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
por: Emin, Derya, et al.
Publicado: (2022)

Correction: Clinical Factors Associated with Abnormal Postures in Parkinson's Disease
por: Oeda, Tomoko, et al.
Publicado: (2013)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
por: Hu, Shanshan, et al.
Publicado: (2020)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
por: Javed, Hayate, et al.
Publicado: (2019)

Dynamics of a model for the degradation mechanism of aggregated α-synuclein in Parkinson's disease
por: Yang, Bojie, et al.
Publicado: (2023)

Anionic Nanoplastic Contaminants Promote Parkinson’s Disease-Associated α-Synuclein Aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Neurodegeneration and the ordered assembly of α-synuclein
por: Spillantini, Maria Grazia, et al.
Publicado: (2017)

Astrocytic expression of Parkinson's disease-related A53T α-synuclein causes neurodegeneration in mice
por: Gu, Xing-Long, et al.
Publicado: (2010)

Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?
por: Post, Michael R., et al.
Publicado: (2018)

α‐synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson’s disease
por: Tu, Hai‐Yue, et al.
Publicado: (2021)

VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson’s disease
por: Chen, Xi, et al.
Publicado: (2023)

The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia
por: Schulz-Schaeffer, Walter J.
Publicado: (2010)

Modelling α-Synuclein Aggregation and Neurodegeneration with Fibril Seeds in Primary Cultures of Mouse Dopaminergic Neurons
por: Tourville, Aurore, et al.
Publicado: (2022)

New Roles of Glycosaminoglycans in α-Synuclein Aggregation in a Cellular Model of Parkinson Disease
por: Lehri-Boufala, Sonia, et al.
Publicado: (2015)

Transcriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's disease
por: Basu, Sambuddha, et al.
Publicado: (2015)

Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson’s disease patients
por: Recasens, Ariadna, et al.
Publicado: (2018)

Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
por: Wang, Zerui, et al.
Publicado: (2020)

Inflammatory Responses to Monomeric and Aggregated α-Synuclein in Peripheral Blood of Parkinson Disease Patients
por: Piancone, Federica, et al.
Publicado: (2021)

Mechanisms of enhanced aggregation and fibril formation of Parkinson’s disease-related variants of α-synuclein
por: Ohgita, Takashi, et al.
Publicado: (2022)

Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson’s disease
por: Hideshima, Makoto, et al.
Publicado: (2022)

Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease
por: Bongianni, Matilde, et al.
Publicado: (2022)

The Aggregation of Huntingtin and α-Synuclein
por: Chánez-Cárdenas, María Elena, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_epc5cf75b0v4isdc7ntjq56vfa